Changes in anxiety sensitivity with pharmacotherapy for panic disorder

Journal of Psychiatric Research
Naomi M SimonMark H Pollack

Abstract

Fear of anxiety symptoms (anxiety sensitivity) has been implicated in the etiology and maintenance of panic disorder, and has been shown to improve with cognitive-behavioral treatment. The impact of pharmacotherapy on anxiety sensitivity is less clear. We administered the Anxiety Sensitivity Index (ASI) during a 12-week randomized controlled trial investigating the relative efficacy of paroxetine, paroxetine plus sustained clonazepam, and paroxetine plus brief clonazepam for patients with panic disorder. We found a mean reduction in ASI scores of 9.6 points, which correlated with symptomatic improvement, and did not differ significantly between groups. Our data provides further evidence that pharmacotherapy leads to significant acute reductions in fears of anxiety symptoms in patients with panic disorder, albeit at levels that may be somewhat less than the changes associated with CBT. Implications of these findings are discussed relative to optimizing pharmacologic treatment of panic disorder.

References

Jan 1, 1986·Behaviour Research and Therapy·D M Clark
Jan 1, 1986·Behaviour Research and Therapy·S ReissR J McNally
Nov 1, 1994·Progress in Neuro-psychopharmacology & Biological Psychiatry·G A FavaF M Saviotti
Jun 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·D M ClarkM Gelder
Aug 1, 1996·The American Journal of Psychiatry·G A Fava
Nov 14, 1997·The American Journal of Psychiatry·M K ShearL A Papp
Mar 31, 2001·Behaviour Research and Therapy·S H StewartS C Borger
Sep 5, 2001·The American Journal of Psychiatry·M K ShearS Masters
Apr 18, 2002·The Journal of Nervous and Mental Disease·Murray B SteinW John Livesley
Nov 20, 2002·Biological Psychiatry·Richard J McNally
Sep 30, 2003·Journal of Psychopharmacology·Mark H PollackMichael W Otto
May 6, 2004·Journal of Anxiety Disorders·Pietra RomanoGiampaolo Perna
Aug 11, 2004·Journal of Consulting and Clinical Psychology·Jasper A J SmitsMichael J Telch

❮ Previous
Next ❯

Citations

Jul 31, 2014·The Journal of Nervous and Mental Disease·Donald J RobinaughNaomi M Simon
Feb 1, 2011·Journal of Anxiety Disorders·E A HogeN M Simon
Jan 13, 2009·Depression and Anxiety·Carlos Israel Pérez BenítezMartin B Keller
Aug 30, 2008·Depression and Anxiety·Jasper A J SmitsMichael W Otto
Nov 26, 2015·The Psychiatric Clinics of North America·Elaine M Boland, Richard J Ross
Mar 1, 2012·Psychiatry Research·Hee-Jin ParkBum-Hee Yu
Aug 9, 2008·Behaviour Research and Therapy·Jasper A J SmitsMark B Powers
Oct 25, 2016·Journal of Psychiatric and Mental Health Nursing·Y S ChoiY Cho
May 9, 2019·Annual Review of Clinical Psychology·Martin P PaulusSahib S Khalsa
Aug 12, 2014·Human Psychopharmacology·Brian H Harvey, Francois N Slabbert
Nov 15, 2014·Psychiatry Investigation·Hye-Min SongBum-Hee Yu
Mar 15, 2019·Scientific Reports·Johanna H M Hovenkamp-HermelinkHarriëtte Riese

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.